We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01033539
First Posted: December 16, 2009
Last Update Posted: March 29, 2012
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Good Food Practice, Sweden
  Purpose
The purpose of this study is to determine the effects of a sachet containing Lactobacillus Reuteri ATCC PTA 4659 on the recovery of live Lactobacillus reuteri in fecal samples after 7, 14 and 28 days supplementation as well as 14 days wash out compared to the same sachet without the probiotic bacteria as placebo control.

Condition Intervention
Recovery of Lactobacillus Reuteri ATCC PTA 4659 The Safety of Lactobacillus Reuteri ATCC PTA 4659 Other: Probiotic strain ATCC PTA 4659

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Basic Science
Official Title: To Demonstrate That Lactobacillus Reuteri ATCC PTA 4659 Survives Passage Through the Gastrointestinal Tract of Humans

Resource links provided by NLM:


Further study details as provided by Good Food Practice, Sweden:

Primary Outcome Measures:
  • Change form baseline to day 28 on treatment in level of live Lactobacillus Reuteri ATC PTA 4659 in faecal material. [ Time Frame: Nov 2009-April2010 ]

Enrollment: 30
Study Start Date: November 2009
Study Completion Date: August 2011
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Placebo control
Placebo control without probiotics ATCC PTA 4659
Other: Probiotic strain ATCC PTA 4659
Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
Other Name: ATCC PTA 4659
Active Comparator: ATCC PTA 4659 Low dose Other: Probiotic strain ATCC PTA 4659
Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
Other Name: ATCC PTA 4659
Active Comparator: ATCC PTA 4659 high dose Other: Probiotic strain ATCC PTA 4659
Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
Other Name: ATCC PTA 4659

Detailed Description:
This study is the first to investigate the relative colonisation of the human GI tract by L Reuteri ATCC PTA 4659. Simple demonstration that they survive passage is the first step in development of potential new probiotics, which is necessary before these strains can be considered for continued testing in probiotic food matrices. The aim of this study will evaluate the safety and tolerability of Lactobacillus Reuteri in healthy adult subjects.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Males and females
  • Age 18-65 years
  • BMI 19-33
  • Hb 120 g/women 130 g/l for men
  • Healthy assessed by screening tests and physical examination
  • Signed informed consent and bio bank consent

Exclusion Criteria:

  • Participation in a clinical study within 90 days prior screening use of antibiotics 2 weeks before baseline
  • Pregnant or lactating
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01033539


Locations
Sweden
Good Food Practice
Uppsala, Sweden, 751 83
Sponsors and Collaborators
Good Food Practice, Sweden
Investigators
Principal Investigator: Birgitta E Sundberg, PhD Good Food Practice, Uppsala, Sweden
  More Information

Responsible Party: Good Food Practice, Sweden
ClinicalTrials.gov Identifier: NCT01033539     History of Changes
Other Study ID Numbers: CSP U-08-008 BSS
First Submitted: December 15, 2009
First Posted: December 16, 2009
Last Update Posted: March 29, 2012
Last Verified: March 2012

Keywords provided by Good Food Practice, Sweden:
Survive
safety
lactobacillus Reuteri